Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event

Proper prescription and high adherence to intensive lipid lowering drugs (LLD) in patients with coronary heart disease (CHD) are crucial and strongly recommended. The aim of this study is to investigate long-term treatment patterns and adherence to LLD following hospitalization for a CHD event. Pati...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2024-06, Vol.393, p.117550, Article 117550
Main Authors: Engebretsen, Ingrid, Bugge, Christoffer, Støvring, Henrik, Husebye, Einar, Sverre, Elise, Dammen, Toril, Halvorsen, Sigrun, Munkhaugen, John
Format: Article
Language:English
Subjects:
Adherence
Aged
Coronary Disease - drug therapy
Coronary heart disease
Dyslipidemias - blood
Dyslipidemias - diagnosis
Dyslipidemias - drug therapy
Dyslipidemias - epidemiology
Ezetimibe - therapeutic use
Female
Follow-Up Studies
Hospitalization
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypolipidemic Agents - therapeutic use
Lipid-lowering treatment
Male
Medication Adherence
Middle Aged
Norway - epidemiology
Practice Patterns, Physicians
Prescription registry
Psychosocial
Rosuvastatin Calcium - therapeutic use
Statins
Time Factors
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proper prescription and high adherence to intensive lipid lowering drugs (LLD) in patients with coronary heart disease (CHD) are crucial and strongly recommended. The aim of this study is to investigate long-term treatment patterns and adherence to LLD following hospitalization for a CHD event. Patients admitted to two Norwegian hospitals with a CHD event from 2011 to 2014 (N = 1094) attended clinical examination and completed a questionnaire, median 16 months later. Clinical data were linked to pharmacy dispensing data from 2010 to 2020. The proportions using high-intensity statin therapy (atorvastatin 40/80 mg or rosuvastatin 20/40 mg) and non-statin LLD after the CHD event were assessed. Adherence was evaluated by proportion of days covered (PDC) and gaps in treatment. Median age at hospitalization was 63 (IQR 12) years, 21 % were female. Altogether, 1054 patients (96 %) were discharged with a statin prescription, while treatment was dispensed in 85 % within the following 90 days. During median 8 (SD 2.5) years follow-up, the proportion using high-intensity statin therapy ranged 62–68 %, whereas the use of ezetimibe increased from 4 to 26 %. PDC
ISSN:0021-9150
1879-1484
1879-1484
DOI:10.1016/j.atherosclerosis.2024.117550